EUCTR2010-020387-38-IT进行中（未招募）不适用
Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients with Chronic Hepatitis B Virus Infection who are HBeAg-positive. - LIRA-B
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Signed Written Informed Consent 2) Target Population a) History of CHB infection defined as HBsAg positive at screening and on at least one other occasion = 24 weeks prior to screening; b) Detectable HBeAg and no detectable HBeAb at screening and at least once = 4 weeks prior to screening; c) Serum ALT 1.3 to < 10 x ULN at screening and on at least 1 other occasion within 24 weeks prior to screening, with no value in the intervening period falling below the ULN; d) HBV DNA by PCR = 100,000 copies/mL (17,200 IU/mL) at screening and presence of detectable HBV DNA at least once = 4 weeks prior to screening; e) No prior IFN therapy; f) Prior HBV nucleos(t)ide therapy allowed but not within 30 days prior to screening; g) Thyroid-stimulating hormone (TSH) and/or T4 within 0.8 to 1.2 times the normal limit, or adequately controlled thyroid function as assessed by the investigator; h) Documented baseline retinal exam performed = 1 year of study randomization; any subjects with diabetes, hypertension, or other risk factors for retinal disease per assessment of the investigator can be included with a documented normal eye exam by a licensed ophthalmologist; i) Pre-treatment liver biopsy performed = 2 years prior to study randomization to characterize preexisting liver status. Patients with compensated cirrhosis will be allowed to participate but will be capped at 10%; patients with cirrhosis must not have decompensated liver disease. 3) Age and Reproductive Status a) Men or women, 18 - 70 years of age; b) Contraception Requirements: Women of childbearing potential (WOCBP, see Section 3.3.3 for definition) and sexually active men with female partners who are WOCBP, must use 2 separate forms of contraception from screening throughout the duration of the study. c) WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of investigational product; d) Women must not be breastfeeding; e) Requirements for male subjects: i) Male subjects (unless vasectomized) with female partners who are WOCBP must agree to inform their females partners of the protocol-specified contraception requirements and pregnancy testing recommendations during treatment and post-treatment, and agree to adhere to these recommendations; ii) Male subjects must confirm that their female sexual partners are not pregnant at the time of screening.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Target Disease Exceptions a) Co-infection with HIV, HCV or hepatitis D virus (HDV); b) Other forms of liver disease (eg, alcoholic, autoimmune, biliary disease, hepatic steatosis). 2) Medical History and Concurrent Diseases a) Current evidence of or history of variceal bleeding, hepatic encephalopathy, or ascites requiring diuretics or paracentesis or evidence of any of these findings on physical examination performed at screening; b) Current evidence of or history of pancreatitis; c) History of bone marrow or organ transplant or therapy with an immunomodulatory agent, cytotoxic agent, or systemic corticosteroids within 2 months of screening; d) Current or known history of cancer (except adequately treated in situ carcinoma of the cervix, or basal or squamous cell carcinoma of the skin) within 5 years prior to screening; e) History of hepatocellular carcinoma (HCC) or for patients without a known history, evidence of HCC as documented by abdominal imaging (eg, ultrasound), within 18 months of study randomization; f) Patients with a screening QTcF > 450 msec (males) or > 470 msec (females), based on the average of 3 or more ECGs (ECGs obtained 5 minutes apart while subject is resting in a supine position). g) Patients with other clinically significant ECG abnormalities (indicative of dysarrhythmia, myocardial ischemia or other serious cardiovascular disorder) at the time of screening in the opinion of the investigator; h) Active substance abuse, such as alcohol, or inhaled or injected drugs, as defined by Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV), Diagnostic Criteria for Drug and Alcohol Abuse (Appendix 1) within 6 months prior to screening. Subjects who are receiving methadone or other substitutive product under medical supervision are eligible. Use of marijuana for medical purpose is allowed; i) Prior or current history of cardiomyopathy or significant ischemic cardiac or cerebrovascular disease, including history of angina, myocardial infarction, interventional procedure for coronary artery disease (including angioplasty, stent procedure, or cardiac bypass surgery); j) Prior or current history of clinically significant hemoglobinopathy or hemolytic anemia; k) Prior or current history of interstitial lung disease or sarcoidosis; l) History of immunologically mediated disease (including, but not limited to, rheumatoid arthritis, inflammatory bowel disease, moderate to severe psoriasis [mild psoriasis is allowed], and systemic lupus erythematosus); m) History of moderate, severe, or uncontrolled psychiatric disease; mild depression controlled at time of screening is allowed; n) Active seizure disorder as defined by either untreated seizure disorder or continued seizure activity within the past year prior to screening despite treatment with anti-seizure medication; o) Has, in the opinion of the investigator, any physical exam findings, laboratory abnormalities, or other medical, social, or psychosocial factors that may negatively impact compliance or subject’s safety by participation in this study; this should include conditions which may affect hematologic parameters such as prior or current history of porphyria cutanea tarda and/or hemophilia. 3) Physical and Laboratory Test Findings a) Hemoglobin < 12.0 g/dL (males) or < 11.0 g/dL (females); b) Platelet count < 90,000/mm?; c) Confirmed creatinine clearance (CrCl) (as estimated by Cockcroft and Gault) = 50 mL/min; d) Total serum bilirubin > 2.5 mg/dL (> 42.75
研究者
相似试验
已完成
2 期
Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients with Chronic Hepatitis B Virus Infection who are HBeAg-positiveChronic hepatitis B virus infection or CHB1001965410047438NL-OMON39072Bristol-Myers Squibb8
进行中（未招募）
1 期
An international trial of deferiprone in patients with Parkinson’s diseaseParkinson’s diseaseMedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-004344-19-GBApoPharma140
进行中（未招募）
1 期
An international trial of deferiprone in patients with parkinson’s diseaseParkinson’s diseaseMedDRA version: 19.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disordersEUCTR2015-004344-19-FRApoPharma Inc.140
进行中（未招募）
1 期
An international trial of deferiprone in patients with Parkinson’s diseaseParkinson’s diseaseMedDRA version: 20.0 Level: PT Classification code 10061536 Term: Parkinson's disease System Organ Class: 10029205 - Nervous system disordersEUCTR2015-004344-19-DEApoPharma140
进行中（未招募）
不适用
Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multinodular GoiterEUCTR2005-004451-35-NLGenzyme Europe BV99